Biomarck is pleased to announce its inclusion on COVID-19 Drug Treatment Trackers: Milken Institute COVID-19 Treatment and Vaccine Tracker | Artis Ventures


Dr. Wheeler joined Biomarck as Chief Medical Officer on a part-time basis in February 2021. Previously, he was Global Head of Clinical Development, Respiratory Medicine and Biotherapeutics at Sunovion Pharmaceuticals and prior to Sunovion, he was Senior Director of Clinical Research at Cubist Pharmaceuticals, Vice President of Medical Affairs at Avant Immunotherapeutics, Director, Respiratory Medicine at Astra USA and a clinical research physician for Glaxo Group Research. Dr. Wheeler brings decades of drug development know-how to the position, including leadership roles in nine successful filings of marketing applications with regulatory agencies worldwide. He has considerable experience in medical and regulatory affairs, with a particular focus on respiratory products and associated indications. At Biomarck, Dr. Wheeler is responsible for all medical and clinical aspects of development, with an initial focus on the clinical development program for BIO-11006 in acute respiratory distress syndrome (ARDS). Dr. Wheeler received his medical doctor degree from the Royal London Hospital Medical College, and his MFPM from the Royal College of Physicians. He is a member of the American Thoracic Society and a former vice president of the American Academy of Pharmaceutical Physicians.